CORDIS · 101137457 · HORIZON
ENT1DEP ENTEROVIRUS-LINKED TYPE 1 DIABETES EXPOSED -MECHANISMS AND PREVENTION
Coordinator: TAMPEREEN KORKEAKOULUSAATIO SR (FI)
ENT1DEP aims to define causal links between infections and NCDs by focusing on enterovirus (EV) infections and type 1 diabetes (T1D), a robust association without proof of causality. Causality is addressed by a multidisciplinary, multi-layer approach, using in-vitro and in-vivo models, unique human samples, and artificial intelligence to identify mechanisms and related biomarkers, asking 3 key questions:1. Why are only insulin-producing β-cells destroyed by EVs? Weak β-cell antiviral responses and high expression of EV entry receptors may favour EV persistence. This hypothesis is addressed us…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €7.1M awarded to the consortium. The project runs over approximately 4 years from 2024-01-01 to 2027-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from FI
see all →- BalticSeaH2 — Cross-border Hydrogen Valley around the Baltic Sea101112047 · HORIZON · €25.0M
- R4C — Regions4Climate101093873 · HORIZON · €24.5M
- LUMI-IQ — LUMI AI Factory - Advanced experimental AI-optimised quantum based platform101239031 · HORIZON · €20.0M
- SPARCs — Sustainable energy Positive & zero cARbon CommunitieS864242 · H2020 · €19.7M
- Qu-Pilot — Experimental production capabilities for quantum technologies in Europe101113983 · HORIZON · €19.0M
- EUDAT2020 — EUDAT2020654065 · H2020 · €18.9M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €7.1M toward a total project budget of €7.1M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-HLTH-2023-DISEASE-03.
- Who coordinates the project?
- The project is coordinated by TAMPEREEN KORKEAKOULUSAATIO SR (FI).
- What is the project timeline?
- The project runs from 2024-01-01 to 2027-12-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101137457.